RSS | Login | Register

ISENTRESS

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare ISENTRESS to:

Generic Name for ISENTRESS

Raltegravir (as potassium) 400mg; tabs.

Legal Classification:

Pharmacological Class for ISENTRESS

HIV-1 integrase strand transfer inhibitor.

Manufacturer of ISENTRESS

Merck & Co., Inc.

Indications for ISENTRESS

HIV-1 infection, in combination with other antiretrovirals.

Adult dose for ISENTRESS

>16yrs: 400mg twice daily. Avoid dosing before dialysis sessions. Cocomitant rifampin: 800mg twice daily.

Children's dosing for ISENTRESS

<16yrs: not recommended.

Warnings/Precautions for ISENTRESS

Severe hepatic impairment. Monitor for immune reconstitution syndrome (esp. during initial therapy), myopathy, rhabdomyolysis. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions for ISENTRESS

Antagonized by rifampin, possibly other strong UGT1A1 inducers. May be potentiated by UGT1A1 inhibitors. Caution with other drugs that can cause myopathy (eg, statins).

Adverse Reactions for ISENTRESS

Insomnia, headache, nausea, asthenia, fatigue, creatinine kinase elevations; others (see literature).

Notes for ISENTRESS

How is ISENTRESS supplied?

Tabs—60

Related Disease:

HIV~antivirals

Abbott RealTime HBV test approved

September 02, 2010

Abbott announced that the FDA has approved its RealTime HBV assay for measuring the amount of hepatitis B virus (HBV) in human plasma or serum from individuals chronically infected with HBV.

Longer use of Valcyte for renal transplant patients approved

August 11, 2010

The FDA has approved a longer duration of therapy with Valcyte (valganciclovir, from Genentech) in adult renal transplant patients at high risk for cytomegalovirus (CMV) disease.

Phase 3 study of boceprevir for the treatment of HCV

August 05, 2010

Merck announced the completion and results of its two Phase 3 studies for boceprevir for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection.

Afluria labeling updated to include fever and febrile seizure risk

August 02, 2010

The Prescribing Information for Afluria (trivalent, inactivated, "split virus" influenza vaccine [Types A and B], from CSL Biotherapies) has been updated to inform healthcare professionals of an increased incidence of fever and febrile seizure among young children in Australia, mainly those <5years of age.

Fluzone available for 2010-2011 influenza season

July 30, 2010

Sanofi Pasteur announced that it has begun shipping the 2010-2011 formulation of Fluzone (trivalent inactivated "split virus" influenza vaccine [Types A and B]).